Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
The Women's Health Initiative (WHI) trial of estrogen plus progestin assessed whether conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) prevents heart disease and hip fractures and increases the risk of breast cancer in 16 608 postmenopausal, predominantly healthy women with an intact uterus who were 50 through 79 years old at study entry. Study outcomes also included stroke, deep vein thrombosis, pulmonary embolism, endometrial cancer, colorectal cancer, hip, vertebral and other fractures, death from all causes, and a global index of benefit and harm.